Every 10-Q that GlucoTrack, Inc. (GCTK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GCTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GCTK filings page.
Glucotrack, Inc. reported a net loss of $8,148k for the six months ended June 30, 2026, an improvement from a $11,589k loss a year earlier, as research and development expenses fell to $4,148k from $5,021k. General and administrative expenses were $3,455k versus $3,273k.
Total assets declined to $1,495k, with cash and cash equivalents dropping to $1,124k from $7,383k, while total liabilities were $3,236k, resulting in a stockholders’ deficit of $1,741k. Operating cash outflow was $7,664k in the first half of 2026.
The company raised equity through its 6B ELOC and warrant exercises, increasing common shares outstanding to 6,259,279 at June 30, 2026 and subsequently completed a Business Combination with Lokahi Therapeutics on July 14, 2026. Management disclosed substantial doubt about the ability to continue as a going concern and highlighted Nasdaq listing deficiencies related to minimum bid price and stockholders’ equity, as well as new Bridge Financing and a $50,000 ELOC facility to support liquidity.
Glucotrack, Inc. reported a larger share count and ongoing losses as it advances development of its implantable continuous blood glucose monitor. For the quarter ended March 31, 2026, the company recorded a net loss of $4,334 thousand, with research and development expenses of $2,132 thousand and general and administrative expenses of $2,071 thousand.
Cash and cash equivalents fell to $3,929 thousand from $7,383 thousand at year-end, and accumulated deficit reached $156,172 thousand. Management states these factors raise substantial doubt about its ability to continue as a going concern and expects to rely on additional equity or debt financings. Subsequent events include an IDE submission to the FDA for a U.S. clinical study, equity raises under an ELOC facility, debt-for-equity exchanges, and a Nasdaq staff determination to delist the stock for failing the $1.00 bid-price rule, which the company plans to appeal.
Glucotrack (GCTK) filed its Q3 2025 10‑Q, reporting an operating loss of $4.3 million and a net loss of $4.2 million for the quarter. For the nine months ended September 30, 2025, net loss was $15.8 million.
Cash and cash equivalents were $7.9 million as of September 30, 2025, up from $5.6 million at year‑end, driven by financing inflows. During 2025, the company raised $10.7 million via equity sales (including ATM issuances) and received $3.0 million from a promissory note. Total assets were $8.3 million, liabilities $5.5 million, and stockholders’ equity $2.8 million. Shares outstanding were 910,688 as of November 13, 2025.
Management disclosed that conditions raise substantial doubt about the company’s ability to continue as a going concern. The company estimates it will require approximately $15.0 million to fund operations over the next twelve months and may seek additional equity or debt financing, including an equity line of up to $20.0 million. Product R&D advanced, with first‑in‑human study results presented and FDA pre‑IDE interactions underway, with an IDE submission expected in Spring 2026. The company also reported material weaknesses in internal control and ongoing remediation.
GlucoTrack, Inc. (GCTK) 10-Q highlights key liquidity, capital-raising and equity-structure actions through June 30, 2025. The company reported cash and cash equivalents of $9,555 and continued operating losses, with multiple periods showing losses (examples include $11,589, $7,416, $4,756, $4,489 reflected across periods). Share count rose materially to 899,410 shares outstanding as of June 30, 2025 from 13,409 at 12/31/2024 following public offerings, private placements and warrant exchanges.
The company completed a February 2025 1-for-20 reverse split and a June 2025 1-for-60 reverse split, and stockholders approved increasing authorized common shares from 100,000,000 to 250,000,000. Financing activity included at-the-market sales and registered offerings generating net proceeds such as $4,320, $3,643, and a private placement raising approximately $500. Derivative warrant liabilities changed, with a June 30, 2025 reported balance movement (fair value adjustments noted). Management states it plans to finance operations via equity or debt and notes there is no assurance of obtaining sufficient financing to continue as a going concern.